Funded Biotechnology Startups in Menlo Park
Menlo Park biotech funding in this list is anchored by a single disclosed outlier: Grail’s $390M round on 2020-05-06.
Menlo Park biotech funding in this list is anchored by a single disclosed outlier: Grail’s $390M round on 2020-05-06. The next-largest disclosed amounts are much smaller (e.g., 180 Life Sciences at $425M on 2025-07-29 and BillionToOne at $130M on 2024-06-21), while several rounds sit in the $40M–$60M band (AN2 Therapeutics $40M on 2026-03-09; Octave $40M on 2023-11-24; 3T Biosciences $40M on 2022-08-25). A cluster is visible in the most recent window: two funding entries landed on 2026-03-09 (AN2 Therapeutics $40M and Forum Markets $10M), with additional rounds in late January–March 2026 (Abram Scientific on 2026-02-25 at $12M; Antheia on 2026-01-27 at $24M). Stage and disclosure are mixed: “Series Unknown” appears on 11 of 26 rows, and disclosed “undisclosed” amounts appear on 2 rows (MedaSystems 2025-03-05; Invenio Imaging 2023-06-06). Dates span 2020-05-06 through 2026-03-09 across 26 entries, all listed in Menlo Park, California.
Most recent rounds
26 shownRelated listings
Frequently asked
What are the largest and smallest disclosed rounds here, and how extreme is the gap?
The largest disclosed amount is 180 Life Sciences at $425M (2025-07-29); the smallest disclosed amount is IncellDx at $500K (2024-07-23). That creates a wide spread between a single mega-round and several mid-size disclosed rounds (for example, $40M at AN2 Therapeutics 2026-03-09 and $40M at Octave 2023-11-24).
Do any rounds cluster tightly by date near the top of the list?
Yes. Two entries share the most recent round date, 2026-03-09 (AN2 Therapeutics $40M and Forum Markets $10M), and there’s a second close grouping across late Jan to Feb 2026 (Antheia $24M on 2026-01-27; Abram Scientific $12M on 2026-02-25).
How often is the round stage not specified, and do “undisclosed” amounts behave differently than “Series Unknown”?
“Series Unknown” appears on 11 of 26 rows (including AN2 Therapeutics 2026-03-09 at $40M and Personalis 2024-12-19 at $50M). Separately, two rows show an “undisclosed” amount (MedaSystems 2025-03-05 and Invenio Imaging 2023-06-06), which limits comparisons based on disclosed size for those two entries.
Which stage labels show up most clearly among disclosed entries (ignoring blanks/unknown), and what does that imply about mix?
Among explicitly labeled stages, Series C is frequent (Antheia 2026-01-27 $24M; Alladapt Immunotherapeutics 2022-06-22 $119M; Allay Therapeutics 2021-09-15 $60M; DiCE Molecules 2021-08-24 $60M). In contrast, several earlier high-value rounds do not provide a stage label (e.g., Strateos on 2021-06-08 at $56M; Grail on 2020-05-06 at $390M), reinforcing that stage disclosure is uneven.
Are there clear funding-size bands that repeat, suggesting multiple cohorts rather than a smooth distribution?
The $40M–$60M band appears repeatedly (AN2 Therapeutics $40M on 2026-03-09; Octave $40M on 2023-11-24; 3T Biosciences $40M on 2022-08-25; Allay Therapeutics $60M on 2021-09-15; DiCE Molecules $60M on 2021-08-24). Outside that band, a small number of entries dominate the upper tail, including 180 Life Sciences at $425M (2025-07-29) and BillionToOne at $130M (2024-06-21).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.